A true theranostic pair – 44/47Sc-labeled GRPR antagonist shows great promise for managing prostate and breast cancer
The high tumor uptake in two cancer entities with elevated expression of GRPR and the tumor response (tumor size and survival rate) highlight the significant theranostic potential of [<sup>44</sup>Sc]Sc/[<sup>47</sup>Sc]Sc-LF1 for PET (scandium-44) and SPECT (scandium-47) imaging and radionuclide targeted therapy.
Authors
- Renata Mikołajczak (ORCID: https://orcid.org/0000-0002-6882-751X)
- Adrianna Bilinska
- Eleni Gourni (ORCID: https://orcid.org/0000-0003-2198-382X)
- Dariusz Pawlak (ORCID: https://orcid.org/0000-0002-3751-0608)
- Tilman Läppchen (ORCID: https://orcid.org/0000-0002-7746-1572)
- Izabela Cieszykowska (ORCID: https://orcid.org/0000-0003-3052-4852)
- Euy Sung Moon (ORCID: https://orcid.org/0000-0003-0447-1355)
- Małgorzata Żółtowska (ORCID: https://orcid.org/0000-0002-4880-1574)
- Axel Rominger (ORCID: https://orcid.org/0000-0002-1954-736X)
- Naveen Kumar (ORCID: https://orcid.org/0000-0001-6176-6913)
- Frank Rösch
- Elena Menéndez
Institutions
- University of Bern (CH)
- Johannes Gutenberg University Mainz (DE)
- University Hospital of Bern (CH)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- National Centre for Nuclear Research (PL)
Publication Details
- Journal
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2025-11-11
- DOI
- https://doi.org/10.1007/s00259-025-07651-y
- Citations
- 1
- Primary Topic
- Radiopharmaceutical Chemistry and Applications
- Type
- article
- Field-Weighted Citation Impact
- 1.36